By Dutch Trader: This year is expected to be an interesting year for Teva Pharmaceuticals (TEVA). The company is becoming more popular again with investors after a long period of skepticism towards the sustainability of Teva's superior earnings momentum. I already wrote an article about Teva on November 15 when the stock price was still around $40. The company now has taken note and is more willing to listen to shareholders where strategy is concerned. This means: more focus on other growth areas besides Biotech pharma products (although these are very successful), more diversification into new growth businesses (generics including biosimilars, OTC medications) and collaboration with other firms. The latest joint venture with Procter&Gamble is a good example. A large number of high-value branded pharmaceuticals have begun to go off-patent, and many more will lose patent exclusivity in the next few years. Major revenue generating blockbuster medicines like Pfizer's (PFE) cholesterol drug Lipitor,Complete Story »